The Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2024 were officially signed into law on 10 April 2025, marking a significant development in the UK clinical trials framework ...

Global pivotal Phase 3 clinical trial would be conducted jointly by Verrica and Torii Pharmaceutical; trial expected to begin in the 1 st half of 2025 Amendment should benefit both parties from a ...

Anixa Biosciences Announces Approval of Protocol Amendment for Ovarian Cancer CAR-T Clinical Trial. ... principal investigator of the trial, stated, "This amendment is a crucial development in our ...

These new rules, called the New Drugs and Clinical Trials (Amendment) Rules, 2024, come into force 1 April 2025. They define a clinical research organization “as the sponsor or a body ...

Amendment to Clinical Protocol for HG-CT-1 to Include Pediatric Patients with R/R AML. LONDON, UNITED KINGDOM / ACCESS Newswire / May 14, 2025 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased ...

Ankyra Therapeutics will provide an update on the status of the ANK-101 Phase 1 ANCHOR clinical trial at ASCO 2024 and has received approval by FDA and Health Canada to amend the Phase I study to ...

Amendment expands the potential benefits of CAR-T therapy allowing a second dose and includes more ovarian cancer histologies. SAN JOSE, Calif., Feb. 18, 2025 /PRNewswire/ -- Anixa Biosciences ...

These new rules, called the New Drugs and Clinical Trials (Amendment) Rules, 2024, come into force 1 April 2025.

Dr. Robert Wenham, Chair of the Gynecologic Oncology Department at Moffitt, and the principal investigator of the trial, stated, "In initial Phase 1 clinical trials, it is customary to begin with ...